PL3741370T3 - Rebamipid do zastosowania w profilaktyce synukleinopatii - Google Patents
Rebamipid do zastosowania w profilaktyce synukleinopatiiInfo
- Publication number
- PL3741370T3 PL3741370T3 PL19020318.2T PL19020318T PL3741370T3 PL 3741370 T3 PL3741370 T3 PL 3741370T3 PL 19020318 T PL19020318 T PL 19020318T PL 3741370 T3 PL3741370 T3 PL 3741370T3
- Authority
- PL
- Poland
- Prior art keywords
- rebamipide
- synucleinopathies
- prevention
- Prior art date
Links
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 title 1
- 208000032859 Synucleinopathies Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229950004535 rebamipide Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19020318.2A EP3741370B1 (en) | 2019-04-30 | 2019-04-30 | Rebamipide for use in prevention of synucleinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3741370T3 true PL3741370T3 (pl) | 2025-04-14 |
Family
ID=66396957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19020318.2T PL3741370T3 (pl) | 2019-04-30 | 2019-04-30 | Rebamipid do zastosowania w profilaktyce synukleinopatii |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220202805A1 (pl) |
| EP (1) | EP3741370B1 (pl) |
| JP (1) | JP2022533005A (pl) |
| KR (1) | KR20220003064A (pl) |
| CN (1) | CN113784715A (pl) |
| AU (1) | AU2020266279A1 (pl) |
| BR (1) | BR112021021681A2 (pl) |
| CA (1) | CA3138389A1 (pl) |
| EA (1) | EA202192961A1 (pl) |
| ES (1) | ES3018292T3 (pl) |
| MX (1) | MX2021013360A (pl) |
| PL (1) | PL3741370T3 (pl) |
| WO (1) | WO2020221892A2 (pl) |
| ZA (1) | ZA202110052B (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112603899A (zh) * | 2020-12-23 | 2021-04-06 | 南京友杰医药科技有限公司 | 瑞巴派特肠溶片及其制备方法 |
| KR20240111158A (ko) * | 2023-01-09 | 2024-07-16 | 주식회사 포스테라헬스사이언스 | 레바미피드 또는 이의 약학적으로 허용 가능한 염을 유효 성분으로 포함하는 서방성 다층정제 및 이의 제조 방법 |
| CN117122572B (zh) * | 2023-09-15 | 2025-11-25 | 广东华南药业集团有限公司 | 一种瑞巴派特片及其制备方法 |
-
2019
- 2019-04-30 PL PL19020318.2T patent/PL3741370T3/pl unknown
- 2019-04-30 EP EP19020318.2A patent/EP3741370B1/en active Active
- 2019-04-30 ES ES19020318T patent/ES3018292T3/es active Active
-
2020
- 2020-04-30 MX MX2021013360A patent/MX2021013360A/es unknown
- 2020-04-30 AU AU2020266279A patent/AU2020266279A1/en not_active Abandoned
- 2020-04-30 BR BR112021021681A patent/BR112021021681A2/pt not_active Application Discontinuation
- 2020-04-30 WO PCT/EP2020/062120 patent/WO2020221892A2/en not_active Ceased
- 2020-04-30 EA EA202192961A patent/EA202192961A1/ru unknown
- 2020-04-30 CA CA3138389A patent/CA3138389A1/en active Pending
- 2020-04-30 US US17/607,048 patent/US20220202805A1/en active Pending
- 2020-04-30 JP JP2021564279A patent/JP2022533005A/ja active Pending
- 2020-04-30 CN CN202080032289.9A patent/CN113784715A/zh active Pending
- 2020-04-30 KR KR1020217039133A patent/KR20220003064A/ko not_active Ceased
-
2021
- 2021-12-06 ZA ZA2021/10052A patent/ZA202110052B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3138389A1 (en) | 2020-11-05 |
| EA202192961A1 (ru) | 2022-01-20 |
| KR20220003064A (ko) | 2022-01-07 |
| ES3018292T3 (en) | 2025-05-14 |
| EP3741370A1 (en) | 2020-11-25 |
| JP2022533005A (ja) | 2022-07-21 |
| US20220202805A1 (en) | 2022-06-30 |
| EP3741370B1 (en) | 2024-12-25 |
| WO2020221892A2 (en) | 2020-11-05 |
| BR112021021681A2 (pt) | 2021-12-21 |
| WO2020221892A3 (en) | 2020-12-24 |
| MX2021013360A (es) | 2022-01-31 |
| ZA202110052B (en) | 2023-11-29 |
| AU2020266279A1 (en) | 2021-12-23 |
| CN113784715A (zh) | 2021-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289754A (en) | Piperidinylmethylpurinamines as nsd2 inhibitors and anticancer agents | |
| IL268030A (en) | Bicyclics as allosteric shp2 inhibitors | |
| PT3468972T (pt) | Compostos e composições para inibir a atividade da shp2 | |
| HRP20190270T1 (hr) | C1-inh pripravci i postupci za prevenciju i liječenje poremećaja povezanih s nedostatkom inhibitora c1 esteraze | |
| IL269637A (en) | Preparations and methods for the treatment of synovial diseases | |
| IL279347A (en) | Gremlin-1 antagonist for cancer prevention and treatment | |
| IL258032B (en) | Compounds and preparations for the treatment of ocular disorders | |
| IL286697A (en) | Neurogulin-4 compounds and methods of use | |
| PL4101454T3 (pl) | Kompozycje do stosowania w leczeniu nadciśnienia | |
| IL271758A (en) | Statin preparations and methods for use in the treatment of synuclein pathologies | |
| ES2856150T5 (en) | Use of an inverse transcriptase inhibitor for the treatment and prevention of degenerative diseases | |
| GB2581876B (en) | Compositions for use in the treatment of endometrial disorder | |
| GB201506654D0 (en) | Formulations for inhibition of PCSK9 for the treatment of hypercholesterolemia | |
| ZA202105399B (en) | Use of spiropidion | |
| IL288797A (en) | Treatment of synoclinopathy | |
| IL283295A (en) | gli1 inhibitors as therapeutic agents | |
| IL286533A (en) | Compounds for use in the treatment of adcy5-related dyskinesia | |
| PT3191112T (pt) | Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura | |
| IL263336A (en) | Compounds for the treatment of symphysiolysis | |
| IL244620A0 (en) | A drug combination including laquinimod for the treatment of multiple sclerosis | |
| IL260274A (en) | Use of inhibitors of pi3k activity or function to treat primary Sjogren's syndrome | |
| HK40017017A (en) | Compositions and methods for treating synucleinopathies |